Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Prospective multicenter study of HX575 (biosimilar epoetin-α) in patients with chronic kidney disease applying a target hemoglobin of 10--12 g/dl.

Hörl WH, Locatelli F, Haag-Weber M, Ode M, Roth K; Epo-PASS study group.

Clin Nephrol. 2012 Jul;78(1):24-32.

PMID:
22732334
2.
3.

Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study.

Haag-Weber M, Krämer R, Haake R, Islam MS, Prischl F, Haug U, Nabut JL, Deppisch R; behalf of the DIUREST Study Group.

Nephrol Dial Transplant. 2010 Jul;25(7):2288-96. doi: 10.1093/ndt/gfq087. Epub 2010 Mar 1.

PMID:
20197284
4.

Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis.

Haag-Weber M, Vetter A, Thyroff-Friesinger U; INJ-Study Group.

Clin Nephrol. 2009 Nov;72(5):380-90.

PMID:
19863881
5.

The impact of residual renal function on survival.

Haag-Weber M.

Nephrol Dial Transplant. 2008 Jul;23(7):2123-6. doi: 10.1093/ndt/gfn096. Epub 2008 Mar 6. No abstract available.

PMID:
18323521
6.

[Influence of new dialysis solutions on clinical results in patients treated with peritoneal dialysis].

Haag-Weber M.

Wien Klin Wochenschr. 2005;117 Suppl 6:89-97. Review. German.

PMID:
16437339
7.

Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.

Brunkhorst R, Bommer J, Braun J, Haag-Weber M, Gill C, Wagner J, Wagener T; German Aranesp Study Group.

Nephrol Dial Transplant. 2004 May;19(5):1224-30. Epub 2004 Feb 19.

PMID:
14993489
8.

Treatment options to intensify hemodialysis.

Haag-Weber M.

Kidney Blood Press Res. 2003;26(2):90-5. Review.

9.

Personal dialysis capacity (PDC(TM)) test: a multicentre clinical study.

Van Biesen W, Carlsson O, Bergia R, Brauner M, Christensson A, Genestier S, Haag-Weber M, Heaf J, Joffe P, Johansson AC, Morel B, Prischl F, Verbeelen D, Vychytil A.

Nephrol Dial Transplant. 2003 Apr;18(4):788-96.

PMID:
12637650
10.

A preceding exchange with polyglucose versus glucose solution modifies peritoneal equilibration test results.

Lilaj T, Dittrich E, Puttinger H, Schneider B, Haag-Weber M, Hörl WH, Vychytil A.

Am J Kidney Dis. 2001 Jul;38(1):118-26.

PMID:
11431191
11.

Is absorption of high-dose oral iron sufficient in peritoneal dialysis patients?

Dittrich E, Puttinger H, Schneider B, Hörl WH, Haag-Weber M, Vychytil A.

Perit Dial Int. 2000 Nov-Dec;20(6):667-73.

PMID:
11216557
12.

Neutrophil beta(2)-microglobulin and lactoferrin content in renal failure patients.

Deicher R, Exner M, Cohen G, Haag-Weber M, Hörl WH.

Am J Kidney Dis. 2000 Jun;35(6):1117-26.

PMID:
10845826
13.

Clinical significance of granulocyte-inhibiting proteins.

Haag-Weber M, Cohen G, Hörl WH.

Nephrol Dial Transplant. 2000;15 Suppl 1:15-6. Review. No abstract available.

PMID:
10737161
14.

Protease dependent activation of endothelial cells by peritoneal dialysis effluents.

Krebs M, Kaun C, Lorenz M, Haag-Weber M, Geiger M, Binder BR.

Thromb Haemost. 1999 Oct;82(4):1334-41.

PMID:
10544924
15.

Influence of the preceding exchange on peritoneal equilibration test results: a prospective study.

Lilaj T, Vychytil A, Schneider B, Hörl WH, Haag-Weber M.

Am J Kidney Dis. 1999 Aug;34(2):247-53.

PMID:
10430970
16.

Ultrasonography of the catheter tunnel in peritoneal dialysis patients: what are the indications?

Vychytil A, Lilaj T, Lorenz M, Hörl WH, Haag-Weber M.

Am J Kidney Dis. 1999 Apr;33(4):722-7.

PMID:
10196015
17.

Iron status and iron supplementation in peritoneal dialysis patients.

Vychytil A, Haag-Weber M.

Kidney Int Suppl. 1999 Mar;69:S71-8. Review.

PMID:
10084290
18.

Tidal peritoneal dialysis for home-treated patients: should it be preferred?

Vychytil A, Lilaj T, Schneider B, Hörl WH, Haag-Weber M.

Am J Kidney Dis. 1999 Feb;33(2):334-43.

PMID:
10023647
19.

New strategies to prevent Staphylococcus aureus infections in peritoneal dialysis patients.

Vychytil A, Lorenz M, Schneider B, Hörl WH, Haag-Weber M.

J Am Soc Nephrol. 1998 Apr;9(4):669-76.

20.

New criteria for management of catheter infections in peritoneal dialysis patients using ultrasonography.

Vychytil A, Lorenz M, Schneider B, Hörl WH, Haag-Weber M.

J Am Soc Nephrol. 1998 Feb;9(2):290-6.

21.

Minimal-change glomerulonephritis associated with infantile autosomal recessive polycystic kidney disease.

Banyai S, Falger J, Haag-Weber M, Hörl WH.

Nephrol Dial Transplant. 1997 Dec;12(12):2726-7. No abstract available.

PMID:
9430881
22.

Immune dysfunction in uremia.

Cohen G, Haag-Weber M, Hörl WH.

Kidney Int Suppl. 1997 Nov;62:S79-82. Review.

PMID:
9350688
23.

Dysfunction of polymorphonuclear leukocytes in uremia.

Haag-Weber M, Hörl WH.

Semin Nephrol. 1996 May;16(3):192-201. Review.

PMID:
8734462
24.

Are granulocyte inhibitory proteins contributing to enhanced susceptibility to infections in uraemia?

Haag-Weber M, Hörl WH.

Nephrol Dial Transplant. 1996;11 Suppl 2:98-100. Review.

PMID:
8804005
25.
26.

The immune system in uremia and during its treatment.

Haag-Weber M, Hörl WH.

New Horiz. 1995 Nov;3(4):669-79. Review.

PMID:
8574597
27.

Verapamil reverses abnormal [Ca2+]i and carbohydrate metabolism of PMNL of dialysis patients.

Hörl WH, Haag-Weber M, Mai B, Massry SG.

Kidney Int. 1995 Jun;47(6):1741-5.

28.

Effect of biocompatible membranes on neutrophil function and metabolism.

Haag-Weber M, Hörl WH.

Clin Nephrol. 1994 Jul;42 Suppl 1:S31-6. Review. No abstract available.

PMID:
7923981
29.

Studies of biocompatibility of different dialyzer membranes: role of complement system, intracellular calcium and inositol-triphosphate.

Haag-Weber M, Mai B, Deppisch R, Göhl H, Hörl WH.

Clin Nephrol. 1994 Apr;41(4):245-51.

PMID:
8026120
30.

Isolation of a granulocyte inhibitory protein from uraemic patients with homology of beta 2-microglobulin.

Haag-Weber M, Mai B, Hörl WH.

Nephrol Dial Transplant. 1994;9(4):382-8.

PMID:
8084451
31.

GIP and DIP: a new view of uraemic toxicity.

Haag-Weber M, Mai B, Cohen G, Hörl WH.

Nephrol Dial Transplant. 1994;9(4):346-7. No abstract available.

PMID:
8084443
32.

Effect of calcium channel blockers on intracellular calcium accumulation.

Haag-Weber M, Hörl WH.

Nephrol Dial Transplant. 1994;9 Suppl 3:24-7. Review.

PMID:
8072720
33.

Impact of continuous ambulatory peritoneal dialysis solutions and clearance of macromolecules on polymorphonuclear neutrophils.

Haag-Weber M, Hörl WH.

Perit Dial Int. 1994;14 Suppl 3:S33-8. Review. No abstract available.

PMID:
7948273
34.

Impaired cellular host defence in peritoneal dialysis by two granulocyte inhibitory proteins.

Haag-Weber M, Mai B, Hörl WH.

Nephrol Dial Transplant. 1994;9(12):1769-73.

PMID:
7708262
35.

Uremia and infection: mechanisms of impaired cellular host defense.

Haag-Weber M, Hörl WH.

Nephron. 1993;63(2):125-31. No abstract available.

PMID:
8450902
37.

Altered cellular host defence in malnutrition and uremia.

Haag-Weber M, Hörl WH.

Contrib Nephrol. 1992;98:105-11. Review. No abstract available.

PMID:
1493720
38.

Effect of malnutrition and uremia on impaired cellular host defence.

Haag-Weber M, Dumann H, Hörl WH.

Miner Electrolyte Metab. 1992;18(2-5):174-85. Review.

PMID:
1465054
39.

Effect of hemodialysis on intracellular calcium in human polymorphonuclear neutrophils.

Haag-Weber M, Mai B, Hörl WH.

Miner Electrolyte Metab. 1992;18(2-5):151-5.

PMID:
1465049
40.

Calcium-dependent neutrophil activation.

Haag-Weber M, Hörl WH.

Contrib Nephrol. 1992;100:269-85. Review. No abstract available.

PMID:
1458907
41.

Alterations of polymorphonuclear leukocyte glycogen metabolism and glucose uptake in dialysis patients.

Haag-Weber M, Hable M, Fiedler G, Blum I, Schollmeyer P, Kreusser W, Hörl WH.

Am J Kidney Dis. 1991 May;17(5):562-8.

PMID:
1902624
42.

Effect of immunosuppressive drugs on the release of metalloproteinases from human polymorphonuclear leukocytes.

Hempelmann U, Haag-Weber M, Hörl WH, Tschesche H.

Transpl Int. 1991 Apr;4(1):26-30.

PMID:
1647775
43.

Neutrophil carbohydrate metabolism in patients with essential hypertension and uremia.

Haag-Weber M, Schollmeyer P, Hörl WH.

Adv Exp Med Biol. 1991;297:151-60. Review. No abstract available.

PMID:
1767748
44.
45.

Failure to detect remarkable hypomagnesemia in renal transplant recipients receiving ciclosporin.

Haag-Weber M, Schollmeyer P, Hörl WH.

Miner Electrolyte Metab. 1990;16(1):66-8.

PMID:
2325594
46.

Metabolic response of neutrophils to uremia and dialysis.

Haag-Weber M, Hable M, Schollmeyer P, Hörl WH.

Kidney Int Suppl. 1989 Nov;27:S293-8. Review.

PMID:
2699999
47.

Endocrine and metabolic abnormalities following kidney transplantation.

Hörl WH, Riegel W, Wanner C, Haag-Weber M, Schollmeyer P, Wieland H, Wilms H.

Klin Wochenschr. 1989 Sep 1;67(17):907-18. Review.

PMID:
2681969
48.

Beta-2-microglobulin and main granulocyte components in hemodialysis patients.

Haag-Weber M, Schollmeyer P, Hörl WH.

Artif Organs. 1989 Apr;13(2):92-6.

PMID:
2650660
49.

Effect of calcium channel blockers on granulocyte activation during hemodialysis.

Haag-Weber M, Poppek C, Ranucht H, Schollmeyer P, Hörl WH.

Contrib Nephrol. 1989;74:106-12. No abstract available.

PMID:
2702126
50.

Neutrophil activation during hemodialysis.

Haag-Weber M, Schollmeyer P, Hörl WH.

Adv Exp Med Biol. 1989;260:27-37. Review.

PMID:
2696369

Supplemental Content

Loading ...
Support Center